Feature
Video
5 key trial insights from AUA 2025
Hear from 5 experts as they recap some of the top data from this year's AUA.
Urology Times® was on-site at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada conducting interviews with experts on key data presented at the meeting. In the following video, we feature 5 interviews with presenting authors of top study readouts.
Specifically, we showcase:
Neal D. Shore, MD, FACS: “Sasanlimab in combination with Bacillus Calmette-Guérin improves event-free survival versus Bacillus Calmette Guérin as standard of care in high-risk non-muscle invasive bladder cancer: Phase 3 CREST study results”
Joseph M. Jacob, MD, MCR: “TAR-200 monotherapy in patients with Bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from SunRISe-1”
Margaret A. Knoedler, MD: “Multicenter randomized trial comparing pulse-modulated holmium:YAG laser versus thulium fiber laser for dusting renal stones”
Félix Guerrero-Ramos, MD, PhD, FEBU: “TAR-200 monotherapy in patients with Bacillus Calmette-Guérin–unresponsive papillary disease–only high-risk non–muscle-invasive bladder cancer: First results from cohort 4 of SunRISe-1”
John L. Gore, MD, MS, FACS: “Radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: Results from the comparison of intravesical therapy and surgery as treatment options (CISTO) study”
These 5 videos represent a snapshot of all of the data that were covered at this year’s meeting. You can view our full AUA 2025 coverage here!
To stay even more informed on the latest from Urology Times, subscribe to our newsletters!
